Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis by Peeraphatdit, Thoetchai (Bee) et al.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Alcohol Rehabilitation Within 30 Days of Hospital Discharge is Associated With Reduced 1 
Readmission, Relapse, and Death in Patients with Alcoholic Hepatitis 2 
3 
Short title: Alcohol rehabilitation in alcoholic hepatitis 4 
5 
Thoetchai (Bee) Peeraphatdit MD1, Patrick S. Kamath MD1, Victor M. Karpyak MD, PhD2, Brian Davis 6 
MD3, Vivek Desai MD4, Suthat Liangpunsakul, MD, MPH5, 6, Arun Sanyal, MD3, Naga Chalasani, MD5, 7 
Vijay H. Shah MD1, Douglas A. Simonetto MD 18 
9 
1 Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 10 
2 Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minnesota 11 
3 Division of Gastroenterology and Hepatology, Department of Medicine, Virginia Commonwealth 12 
University, Richmond 13 
4 Department of Family Medicine, The Institute for Family Health, New York, NY 14 
5 Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of 15 
Medicine, Indianapolis, IN 16 
6 Roudebush Veterans Administration Medical Center, Indianapolis, IN 17 
18 
19 
20 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Peeraphatdit, T. (Bee), Kamath, P. S., Karpyak, V. M., Davis, B., Desai, V., Liangpunsakul, S., … Simonetto, D. A. (2019). 
Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in 
Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2019.04.048
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 2 of 21 
 
Corresponding author:  1 
Douglas A. Simonetto 2 
Division of Gastroenterology 3 
Mayo Clinic — Rochester 4 
200 First Street SW 5 
Rochester, MN 55905 6 
Phone: (507) 284-2511 7 
Email: Simonetto.douglas@mayo.edu 8 
 9 
Abbreviations List: 10 
ABIC Age, serum Bilirubin, international normalized ratio, and serum Creatinine 11 
AH Alcoholic hepatitis 12 
BMI Body mass index 13 
CTP Child-Turcotte-Pugh scores 14 
mDF Maddrey discriminant 15 
MELD Model for End-Stage Liver Disease 16 
PT Prothrombin time 17 
INR International normalized ratio  18 
 19 
Word count: 3,994 20 
Abstract word count: 335 21 
Number of figures and tables: 5 22 
Number of supplemental figures and tables: 6 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 3 of 21 
 
Contributor and guarantor information: 1 
Thoetchai (Bee) Peeraphatdit developed the concept, acquired and analyzed the data, drafting the 2 
manuscript; Patrick Kamath, Vijay Shah and Douglas Simonetto designed the study, developed the 3 
concept and critically revised the paper; Brian Davis and Vivek Desai acquired and analyzed the data; 4 
Victor Karpyak, Suthat Liangpunsakul, Arun Sanyal and Naga Chalasani critically revised the paper. 5 
 6 
Conflict of interest:  7 
The authors who have taken part in this study declared that they do not have any conflict of interest with 8 
respect to this manuscript. The work was supported by the NIAAA U01AA 021788 grant to PSK and VHS 9 
  10 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 4 of 21 
 
Background & Aims: Patients admitted to the hospital for alcoholic hepatitis (AH) are at increased risk of 1 
readmission and death. We aimed to identify factors associated with readmission, alcohol relapse, and 2 
mortality. 3 
Methods: We performed a retrospective analysis of consecutive patients admitted with AH to a tertiary 4 
care hospital from 1999 through 2016 (test cohort, n=135). We validated our findings in a prospective 5 
analysis of patients in a multi-center AH research consortium from 2013 through 2017 (validation cohort, 6 
n=159). Alcohol relapse was defined as any amount of alcohol consumption within 30 days after hospital 7 
discharge. Early alcohol rehabilitation was defined as residential or outpatient addiction treatment or 8 
mutual support group participation within 30 days after hospital discharge. 9 
Results: Thirty-day readmission rates were 30% in both cohorts. Alcohol relapse rates were 37% in the 10 
test and 34% in the validation cohort. Following hospital discharge, 27 patients (20%) in the test cohort 11 
and 19 patients (16%) in the validation cohort attended early alcohol rehabilitation. There were 53 deaths 12 
(39%) in a median follow-up time of 2.8 years and 42 deaths (26%) in a median follow-up time of 1.3 13 
years, respectively.  In the test cohort, early alcohol rehabilitation reduced odds for 30-day readmission 14 
(adjusted odds ratios [AOR] 0.16; 95% CI, 0.04–0.65; P=.01), 30-day alcohol relapse (AOR, 0.11; 95% 15 
CI, 0.02–0.53; P<.001), and death (adjusted hazard ratio [AHR], 0.20; 95% CI, 0.05–0.56; P=.001). In the 16 
validation cohort early alcohol rehabilitation reduced odds for 30-day readmission (AOR, 0.30; 95% CI, 17 
0.09–0.98; P=.04), 30-day alcohol relapse (AOR 0.09; 95% CI, 0.01–0.73; P=.02), and death (AHR, 0.20; 18 
95% CI, 0.01–0.94; P=.04). A model combining alcohol rehabilitation and bilirubin identified patients with 19 
readmission to the hospital within 30 days with an area under the receiver operating characteristic curve 20 
of 0.73. 21 
Conclusions: In an analysis from two cohorts of patients admitted with AH, early alcohol rehabilitation 22 
can reduce risk of hospital readmission, alcohol relapse, and death and should be considered as a quality 23 
indicator in AH hospitalization treatment. 24 
Keywords: chemical dependency; addiction treatment; alcohol use disorder; alcohol abstinence 25 
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Introduction 1 
Alcoholic hepatitis or alcohol-associated hepatitis (AH) is the most severe form of alcohol related liver 2 
disease (ALD) and accounts for 0.71% of all admissions in the United States with in-hospital mortality rate 3 
up to 46%.1, 2 Patients surviving an admission for AH are at increased risk of readmission and subsequent 4 
death. Previous studies have mainly evaluated short-term mortality outcomes,3, 4 while other clinically 5 
important outcomes i.e. alcohol relapse and hospital readmission after surviving an index AH admission 6 
have not been well studied. 7 
In patients surviving an AH admission, preventing alcohol relapse is crucial because long-term survival is 8 
dependent on abstinence rather than severity of liver disease.5 Medical therapy with corticosteroids 9 
improve short-term survival and no pharmacologic intervention has been shown to improve long-term 10 
survival.4 Thus, it is important to prevent alcohol relapse after hospital discharge to ensure long-term 11 
alcohol abstinence. Previous studies reported alcohol relapse rates in this population as high as 25% at 12 
1-year5 and 60% at 5-years follow up.6 Multidisciplinary teams including addiction specialists are 13 
recommended in treating patients with ALD.2 However, this integrated approach is prevalent only in liver 14 
transplant settings.7  A gap in knowledge is whether participation in alcohol rehabilitation programs after 15 
hospital discharge can improve clinical outcomes in patients with AH. 16 
In addition to early alcohol relapse, early hospital readmission is another important clinical outcome of AH 17 
that has not been well studied. Hospital readmissions are associated with increased costs to the 18 
healthcare system, patient mortality, and may be preventable.8 Therefore, 30-day readmission rate has 19 
become a key quality indicator used by Center for Medicare and Medicaid Services (CMS) to assess 20 
reimbursement penalties.9 For these reasons, it is pertinent to evaluate the rate of 30-day hospital 21 
readmission in patients with AH. 22 
The aims of the study were to determine the rates and predictors of 30-day readmission, 30-day alcohol 23 
relapse, and mortality after surviving an index AH admission. 24 
  25 
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Patients and Methods 1 
Patient cohorts 2 
The test cohort (N=135) was derived retrospectively from consecutive patients admitted with AH at Mayo 3 
Clinic (Rochester, MN) between 1999 and 2016. A validation cohort (n=159) was derived prospectively 4 
from the ongoing NIAAA Translational Research and Evolving Alcoholic Hepatitis Treatment (TREAT) 5 
consortium 001 study including patients admitted with AH at three tertiary care hospitals: Mayo Clinic 6 
(Rochester, MN), Indiana University (Indianapolis, IN), and Virginia Commonwealth University (Richmond, 7 
VA), between 2013 and 2017. The consortium design has been reported previously.10, 11 Overlapping 8 
patients were removed from the test cohort (n=19). Exclusion criteria include 1) death during index 9 
admission (n=15 and n=5 in test and validation cohort) and 2) Patients who died or were lost to follow 10 
within 1 month after hospital discharge (n=29 and n=50 in test and validation cohort) and 3) Patients who 11 
had previously undergone liver transplantation (n=3 in test cohort). The study was approved by the 12 
institutional review boards (IRB) for all study sites. Some patients included in the validation cohort have 13 
been included in other papers published previously by the TREAT consortium.10-14 14 
Clinical criteria for alcoholic hepatitis diagnosis 15 
As per NIAAA clinical criteria,15 the AH diagnosis was based on the average daily ethanol consumption of 16 
more than 40 g/day for women and more than 60 g/day for men for a minimum of 6 months and within the 17 
6 weeks before study enrollment; and on clinical evaluation and appropriate laboratory testing as defined 18 
by a total bilirubin concentration greater than 3 mg/dL and an aspartate aminotransferase (AST) 19 
concentration greater than 50 U/L, and AST to alanine aminotransferase (ALT) ratio of > 1.5. When the 20 
diagnosis of AH remained in question, a liver biopsy was obtained for confirmation of AH. Patients with 21 
suspected or proven cirrhosis were eligible for enrollment if they met inclusion criteria for AH. Individuals 22 
with positive hepatitis B or hepatitis C virus markers were eligible for enrollment to include the full 23 
spectrum of AH patients seen in clinical practice. However, cases with current or previous diagnosis of 24 
autoimmune hepatitis, drug induced liver disease, hemochromatosis, or Wilson disease were excluded.  25 
Data collection at the time of admission  26 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 7 of 21 
 
Baseline data were collected on (1) demographic factors, body mass index (BMI) and average number of 1 
alcohol drinks per day (1 standard drink equals 12-14 grams of pure alcohol) (2) hepatic decompensation 2 
(ascites, variceal bleeding, hepatic encephalopathy); (3) laboratory values (4) AH severity scores: 3 
Maddrey discriminant (mDF); Model for End-Stage Liver Disease (MELD); Age, serum bilirubin, 4 
international normalized ratio (INR), and serum Creatinine (ABIC); and Child-Turcotte-Pugh (CTP) 5 
scores16, 17 and (5) the use of alcohol relapse prevention medications during admission. 6 
Follow up 7 
In test cohort, subjects were followed until death or last follow up date or August 5, 2017. Alcohol relapse 8 
was based on patient’s report and/or detection of ethanol or its metabolites in urine or blood. In the 9 
validation cohort, subjects were followed for 1 year after enrollment. Follow up included telephone call at 10 
1 month, clinic visit at 6 months, and clinic visit at 1 year, in addition to regular clinical follow up. At each 11 
follow up visit, trained interviewers asked subjects about attendance to alcohol rehabilitation, and hospital 12 
readmission. The latter was confirmed by review of the medical records. At each follow up visit, subjects 13 
self-reported alcohol consumption in the past 30 days using a validated timeline followback 14 
questionnaire.18 Alcohol biomarkers (i.e. blood ethanol level or urine ethyl glucuronide) were not routinely 15 
collected and were collected at the discretion of the medical providers.  16 
Outcomes of interest 17 
The 30-day hospital readmission was defined as any hospital admission within 30 days after discharge. 18 
Alcohol relapse was defined as any alcohol consumption within 30 days after hospital discharge. Early 19 
alcohol rehabilitation was defined as attending either residential or outpatient addiction treatment or 20 
mutual support group (i.e. alcoholics anonymous) within 30 days after hospital discharge. Mortality status 21 
was collected at the time of last follow up or August 5, 2017 for test cohort, and at last follow up or at one 22 
year for the validation cohort. 23 
Statistical analysis 24 
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The rates of 30-day hospital readmission, 30-day alcohol relapse, and death at last follow up were 1 
evaluated. Multivariable Logistic regression analysis was performed to determine independent predictors 2 
for 30-day hospital readmission and 30-day alcohol relapse. The prognostic model for 30-day hospital 3 
readmission (AH readmission score) was developed using independent predictors from the test cohort 4 
and validated in the validation cohort. The performance of the AH readmission score was evaluated using 5 
the area under the receiver operating characteristics (AUC). Multivariable Cox regression analysis was 6 
performed to determine independent predictors of mortality.  Landmark analysis was performed, i.e. all 7 
patients were alive at 30 days after hospital discharge, thus limiting the immortal time bias associated 8 
with alcohol rehabilitation attendance. Variables with P<.05 in the univariate analysis were included in the 9 
multivariable model to identify independent predictors for each outcome. All statistical analyses were 10 
performed using JMP statistical software, version 9.0 (SAS Institute Inc, Cary, NC). All comparisons were 11 
2-sided. P<0.05 was considered statistically significant. 12 
13 
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Results 1 
Baseline characteristics 2 
After excluding patients who were lost to follow up, there were 135 and 159 patients in the test and 3 
validation cohorts respectively. Baseline clinical characteristics of both cohorts are shown in Table 1. In 4 
the test cohort, mean age was 48.0±10.2 years and mean MELD score was 20.5±7.2. In the validation 5 
cohort, mean age was 50.0±11.0 years old and mean MELD score was 21.8±7.2. Alcohol relapse 6 
prevention medications (all were gabapentin) were prescribed to 10(7.4%), and 7(4.4%) patients in test 7 
and validation cohorts respectively. Of 10 patients who received gabapentin in test cohort, five were for 8 
alcohol use disorder and the others were for combination of alcohol use disorder and neuropathic pain. 9 
Alcohol rehabilitation within 30 days after hospital discharge 10 
In the test cohort, 96 out of 135(71.1%) patients were referred for evaluation by alcohol addiction 11 
specialists (either board certified addiction psychiatrists or licensed alcohol and drug counselor) during 12 
index admission, and complete evaluation was performed in 87 out of 135(64.4%) patients. The main 13 
reason for incomplete evaluation was patient’s refusal. This information was not available in the validation 14 
cohort. 15 
Alcohol rehabilitation data was available in all patients in the test cohort and in 74.8% (119 out of 159 16 
patients) in the validation cohort. The analyses evaluating the effect of alcohol rehabilitation were 17 
performed using only cases with available data. There were 27(20.0%) and 19(16.0%) patients attended 18 
alcohol rehabilitation in test and validation cohort, respectively (Table 1). The types of alcohol 19 
rehabilitation were residential rehabilitation (n=12, n=11), outpatient rehabilitation (n=12, n=2), and mutual 20 
support group, i.e. alcoholics anonymous (n=3, n=6) in test and validation cohort respectively.  21 
Next, we evaluate predictors of alcohol rehabilitation attendance. Patients who attended alcohol 22 
rehabilitation were more likely to be evaluated by alcohol addiction specialists and have college degrees 23 
(Supplemental Table 1). Interestingly, the liver severity scores were not different between the two groups. 24 
For test cohort, evaluation by alcohol addiction specialists was a predictor of attending alcohol 25 
rehabilitation (OR 2.91 [95%CI 1.02-8.27], P=0.03) in univariate analysis (Supplemental Table 2) but not 26 
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in multivariable analysis (Supplemental Table 3). For validation cohort, having college degree or above 1 
(AOR 4.62 [95%CI 1.19-17.9], P=0.03) was an independent predictor of attending alcohol rehabilitation in 2 
multivariable analysis (Supplemental Table 3). 3 
30-day readmission after hospital discharge 4 
The 30-day readmission rate was 30.4% (n=41) and 30.8% (n=49) in test and validation cohorts, 5 
respectively (Figure 1). The 30-day readmission rate was lower in those who attended early alcohol 6 
rehabilitation compared to those who did not attend alcohol rehabilitation in both test (11.0% vs. 35.2%, 7 
P=0.02) and validation cohorts (21.1% vs. 45.0%, P=0.07) (Figure 1).  8 
In test cohort, patients readmitted within 30 days were less likely to attend alcohol rehabilitation (7.3% vs. 9 
25.5%, P=0.02) and were more likely to experience alcohol relapse within 1 month after hospital 10 
discharge (56.1% vs 28.7%, P=0.003) (Table 1). Patients readmitted within 30 days had higher rates of 11 
hepatic decompensation, higher total bilirubin level and higher CTP score compared to those without 12 
readmission. Similarly, in validation cohort, patients readmitted within 30 days were less likely to attend 13 
alcohol rehabilitation (8.2% vs. 21.4%, P=0.04) and were more likely to experience alcohol relapse 14 
(57.5% vs 22.3%, P=0.003). Additionally, patients with readmission were more likely to have higher 15 
MELD and CTP scores compared to those without readmission. 16 
In test cohort, causes of readmission included hepatic decompensation (39%), recurrent AH (19%), 17 
infection (15%), other medical conditions (19%) and alcohol intoxication or withdrawal (8%).  In validation 18 
cohort, causes of readmission included hepatic decompensation (51%), other medical conditions (29%), 19 
infection (12%), alcohol intoxication or withdrawal (6%) and recurrent AH (2%).   20 
For test cohort, early alcohol rehabilitation was a protective factor (AOR 0.16 [95%CI 0.04-0.65], P=0.01) 21 
and increase in total bilirubin (AOR 1.04 [95%CI 1.09-0.96, P=0.04) was a risk factor for 30-day 22 
readmission in multivariable analysis after adjusting for hepatic decompensation (Table 2). For validation 23 
cohort, early alcohol rehabilitation was a protective factor against 30-day readmission (AOR 0.30 [95%CI 24 
0.09-0.98], P=0.04) after adjusting for hepatic decompensation and total bilirubin level. Univariate 25 
analysis is shown in Supplemental Table 4. 26 
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To generate an AH readmission score for 30-day readmission, independent predictors of readmission in 1 
the test cohort were used. The AH readmission score = -1.32 + 0.06*(total bilirubin) – 1.80*(alcohol 2 
rehabilitation attendance: yes=1, no=0). The area under the receiver operating characteristic curve (AUC) 3 
for the AH readmission score were 0.73 (95%CI 0.64-0.80) in test cohort and 0.64 (95%CI 0.54-0.72) in 4 
validation cohort (Figure 2). 5 
Alcohol relapse within 30 days after hospital discharge 6 
The 30-day alcohol relapse data were available in all patients in test cohort and in 88.7% (141 out of 159) 7 
in validation cohort.  The 30-day alcohol relapse rate was 37.0% (n=50) and 34.0% (n=48) in test and 8 
validation cohort, respectively (Figure 1). The 30-day alcohol relapse was lower in those who attended 9 
early alcohol rehabilitation compared to those who did not attend alcohol rehabilitation in both test (7.4% 10 
vs. 44.4%, P<0.001) and validation cohorts (5.3% vs. 45.9%, P<0.001) (Figure 1). Among those who 11 
relapsed, only 2 out of 50 in test cohort and only 1 out of 48 in the validation cohort attended alcohol 12 
rehabilitation after hospital discharge. 13 
In univariate analysis (Supplemental Table 5), early alcohol rehabilitation was a protective factor for 30-14 
day alcohol relapse in both test and validation cohorts. Additionally, higher MELD score, CTP score, mDF 15 
scores, INR and having college degree were protective factors for alcohol relapse. In multivariable 16 
analysis (Table 2), participation in alcohol rehabilitation within 30-days after hospital discharge was the 17 
only independent protective factor against 30-day alcohol relapse (AOR 0.11, [95%CI 0.02-0.53], P<0.001 18 
and AOR 0.09, [95%CI 0.01-0.73], P=0.02) in test and validation cohort, respectively. 19 
Mortality 20 
There were 53 (39.3%) and 42 (26.4%) deaths during a median follow up time of 2.8 and 1.3 years in test 21 
and validation cohorts, respectively. The mortality rate at one year was 14% in the test and 16% in the 22 
validation cohort.  As shown in Figure 3, patients who attended early alcohol rehabilitation had 23 
significantly improved survival compared to patients who did not attend alcohol rehabilitation in both test 24 
and validation cohorts.  25 
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Univariate analysis is shown in Supplemental Table 6. In multivariable analysis (Table 2), attendance to 1 
early alcohol rehabilitation was an independent protective factor (adjusted hazard ratio [AHR] 0.20 2 
[95%CI 0.05-0.56], P=0.001), while variceal bleeding was an independent predictor of mortality (AHR 3 
11.1 [95%CI 2.52-34.4], P=0.004) after adjusting for age and sex. In validation cohort, attendance to 4 
alcohol rehabilitation was an independent protective factor (AHR 0.20 [95%CI 0.01-0.94], P=0.04), 5 
whereas age (AHR 1.04 [95%CI 1.01-1.08], P=0.04) and hepatic decompensation (AHR 2.11 [95%CI 6 
1.01-4.99], P=0.04) were significant predictors of mortality, after adjusting for sex and ABIC score. 7 
  8 
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Discussion 1 
Recent studies on AH reported that alcohol relapse is the most important predictor of long-term 2 
mortality.5, 6 However, hospital readmission rates, alcohol relapse along with alcohol rehabilitation 3 
attendance have not been well characterized in the AH population. We utilized a test (single-center 4 
retrospective) and a validation (multi-center prospective) cohort of hospitalized AH patients to evaluate 5 
30-day readmission, 30-day alcohol relapse, and long-term mortality. At 30-days after surviving AH 6 
admission, readmission rate was 30%, alcohol relapse rate was 34-37%, and only 16-20% of patients 7 
participated in alcohol rehabilitation. The current study showed that alcohol rehabilitation after hospital 8 
discharge was associated with decreased 30-day readmission, decreased 30-day alcohol relapse and 9 
importantly, decreased mortality. While alcohol rehabilitation is routinely recommended in this clinical 10 
scenario, this is one of the first studies that documents the benefits of this intervention on clinically 11 
significant patient endpoints including mortality. 12 
In multivariable analysis, participating in alcohol rehabilitation was associated with 70-84% lower risk of 13 
30-day readmission, 89-91% lower risk of 30-day alcohol relapse, and 80% lower risk of long-term 14 
mortality. This is an important finding because alcohol relapse is the most important predictor for long-15 
term mortality and there is currently no proven pharmacological intervention to prevent alcohol relapse in 16 
patients with AH.5, 6, 19, 20 Evidence suggests that psychosocial interventions including cognitive behavioral 17 
therapy and motivational interviewing may be effective in supporting alcohol abstinence in patients with 18 
alcoholic cirrhosis.21-23 It is also important to emphasize that the most common type of alcohol 19 
rehabilitation was at a residential (44% in test cohort and 53% in validation cohort) level of care. Future 20 
studies are necessary to test whether the intensity of treatment along with timelines (within 30 days of 21 
discharge) are important prerequisites of success. 22 
After AH admission, only 16-20% of patients with AH attended alcohol rehabilitation. The results 23 
challenge us to do better as a specialty in connecting patients who survive AH episodes to alcohol 24 
rehabilitation and to build stronger bridges with our addiction specialist colleagues. Our study results 25 
strongly suggest that alcohol rehabilitation should be arranged for AH patients during their index hospital 26 
admission and early alcohol rehabilitation referral should be documented as a quality metric in the 27 
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management of all hospitalized AH patients. Patients evaluated by alcohol addiction specialists during 1 
their hospitalization demonstrated higher attendance rates of alcohol rehabilitation compared to patients 2 
who were not assessed (25.3% vs. 10.4%). Therefore, an addiction specialist should meet with the 3 
patient during hospital admission. Unfortunately, less than 8% of patients received alcohol relapse 4 
prevention medication, which were all gabapentin. It is important to note that the use of gabapentin was 5 
an off-label use.24 The integration of addiction medicine in hepatology practice is becoming even more 6 
important with the development of effective treatments for hepatitis C viral(HCV) infection because 7 
alcohol abstinence is necessary for optimal treatment of HCV.20 8 
Our results emphasize the high disease burden of AH. The 30-day readmission rate was 30%, which is 9 
comparable to patients with decompensated cirrhosis (32%).25 Recurrent AH and alcohol intoxication or 10 
withdrawal were causes of readmission in 19% and 8% in the test cohort, respectively. A previous study 11 
suggested that subsequent episodes of AH in alcohol relapsers are more severe compared to the index 12 
episode with close to 60% mortality.26 Only total bilirubin at the time of admission and participation in 13 
alcohol rehabilitation after hospital discharge were independent predictors of readmission. Interestingly, 14 
the liver severity scores, e.g. MELD score or CTP score, were not predictors for readmission. In contrast, 15 
MELD score has been previously found to be an independent predictor of readmission in cirrhotic 16 
patients.27 Although we attempted to create a model to predict 30-day readmission using alcohol 17 
rehabilitation attendance and total bilirubin, the AUC were only 0.73 and 0.63 in test and validation 18 
cohorts, respectively. Unfortunately, the risk of readmission in this patient population is likely difficult to 19 
predict due to many socioeconomic factors involved. Similar findings have been reported in patients with 20 
decompensated cirrhosis.28 21 
The major strengths of our study were the utilization of two separate cohorts. Importantly, the validation 22 
group was a multicenter prospective cohort with well-defined AH patients. The findings from both cohorts 23 
were consistent. However, our study has few limitations worth mentioning. First, the diagnosis of AH was 24 
made without a liver biopsy, as is common in real practice, which may occasionally lead to misdiagnosis. 25 
However, using the NIAAA clinical criteria, less than 10% of patients would have a diagnosis other than 26 
AH on liver biopsy.15 Second, alcohol relapse was based on self-report and the data may not be fully 27 
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accurate.  However, the well validated timeline followback questionnaire was used and we considered 1 
any alcohol consumption after discharge as relapse. Future studies should include blood or urine markers 2 
to screen for alcohol relapse. Third, we were not able to evaluate the effect of central obesity, factor 3 
shown to have negative effect on outcomes in patients with alcoholic hepatitis.29 This is because waist 4 
and hip circumference data were not available. However, BMI data was analyzed and did not affect the 5 
outcomes in our cohort. Lastly, the reasons for patients not attending rehabilitation are difficult to 6 
ascertain and the benefit of rehabilitation may be reflective of the high motivation of those patients to 7 
discontinue alcohol rather than the rehabilitation process itself.   8 
In conclusion, the 30-day readmission and 30-day alcohol relapse rates are 30% and 37% respectively 9 
after an AH admission. Early alcohol rehabilitation is associated with reduction in hospital readmission, 10 
alcohol relapse, and death and should be pursued in all AH patients during and/or immediately following 11 
their hospitalization. 12 
  13 
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Figure legends 1 
 2 
Figure 1. Rates of 30-day readmission and 30-day alcohol relapse  3 
 4 
Figure 2. Area under the receiver operating characteristic curve of AH readmission score for predicting 5 
30-day readmission in A) test and B) validation cohort. 6 
 7 
Figure 3. Kaplan–Meier curves showing in patients attending vs. not attending alcohol rehabilitation in A) 8 
test and B) validation cohort 9 
 10 
 11 
 12 
 13 
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Table 1.  Baseline characteristics of retrospective and prospective cohort 1 
 Test cohort Validation cohort 
 All patients 
 
(n=135) 
Readmission 
in 30 days  
(n=41) 
No 
readmission  
 (n=94) 
P* All patients 
 
(n=159) 
Readmission 
in 30 days  
(n=49) 
No 
readmission 
(n=110) 
P** 
Age, years 
(mean±SD) 
48.0±10.2 47.2±8.7 48.4±10.8 0.50 50.0±11.0 48.4±12.0 50.8±10.5 0.24 
Male (n, %) 90 (66.7%) 29 (70.7%) 61 (64.9%) 0.51 92 (57.9%) 29 (59.2%) 63 (57.3%) 0.82 
BMI, kg/m2 
(mean±SD) 
28.6±7.4 28.4±7.7 28.7±7.3 0.86 28.9±7.0 28.2±6.0 29.2±7.3 0.33 
White (n, %) 130 (96.3%) 39 (95.1%) 91 (96.8%) 0.64 137 (86.2%) 41 (83.7%) 96 (87.3%) 0.54 
Married or living 
with significant other 
(n, %) 
42 (31.1%) 14 (33.3%) 28 (29.8%) 0.61 59 (40.1%) 21 (44.7%) 38 (38.0%) 0.44 
College degree or 
above (n, %) 
n/a n/a n/a  73 (49.7%) 25 (53.2%) 48 (48.0%) 0.56 
Average number of 
drinks/day 
(median, IQR) 
n/a n/a n/a  8 (5, 13) 7 (5, 11) 9 (5, 15) 0.12 
Hepatic 
decompensation (n, 
%) 
49 (36.3%) 22 (53.7%) 27 (28.7%) 0.006 106 (66.7%) 35 (71.4%) 71 (64.6%) 0.40 
- Hepatic 
encephalopathy (n, 
%) 
17 (12.6%) 7 (17.1%) 10 (10.6%) 0.30 40 (25.2%) 10 (20.4%) 30 (27.3%) 0.35 
- Variceal bleeding 
(n, %) 
3 (2.2%) 2 (4.9%) 1 (1.7%) 0.22 24 (15.1%) 8 (16.3%) 16 (14.6%) 0.77 
- Ascites (n, %) 53 (39.3%) 20 (48.8%) 33 (35.1%) 0.13 90 (56.6%) 29 (59.2%) 61 (55.5%) 0.66 
Use of alcohol 
relapse prevention 
medication 
10 (7.4%) 5 (12.2%) 5 (5.3%) 0.17 7 (4.4%) 0 (0%) 7 (6.4%) 0.10 
Labs 
        
Platelet, 109/L 
(median, IQR) 
147 (86, 
196) 
159 (122, 
205) 
129 (78, 
190) 
0.02 127 (87, 184) 119 (74, 
184) 
130 (87, 
187) 
0.76 
Albumin, g/dL 
(median, IQR) 
3.0 (2.7, 3.4) 3.1 (2.5, 3.3) 3.0 (2.7, 3.5) 0.17 2.8 (2.4, 3.2) 2.8 (2.3, 3.2) 2.8 (2.4, 3.3) 0.51 
Creatinine, mg/dL 
(median, IQR) 
0.7 (0.6, 1.1) 0.6 (0.5, 1.0) 0.7 (0.6, 1.1) 0.10 0.7 (0.6, 1.1) 0.82 (0.63, 
1.2) 
0.7 (0.6, 1.0) 0.45 
Total bilirubin, 
mg/dL (median, 
IQR) 
8.7 (4.0, 
19.6) 
14.4 (6.3, 
23.5) 
6.9 (3.7, 
14.3) 
0.004 9.6 (3.9, 
19.1) 
13.3 (5.5, 
19.1) 
8.3 (3.5, 
19.4) 
0.25 
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INR (median, IQR) 1.4 (1.2, 1.7) 1.5 (1.3, 1.8) 1.3 (1.2, 1.7) 0.21 1.7 (1.4, 2.1) 1.8 (1.5, 2.1) 1.6 (1.3, 2.1) 0.19 
PT, seconds 
(median, IQR) 
15 (13, 19) 15 (13, 18) 15 (12, 19) 0.52 20 (16, 23) 20 (18, 23) 19 (15, 27) 0.07 
Severity scores 
        
MELD score 
(mean±SD) 
20.5±7.2 21.6±6.8 20.0±7.4 0.22 21.8±7.2 23.3±6.7 21.2±7.3 0.04 
CTP score 
(mean±SD) 
8.9±1.5 9.3±1.3 8.8±1.6 0.03 9.5±1.8 9.9±1.5 9.4±1.9 0.04 
mDF score (median, 
IQR) 
30 (16, 50) 37 (19, 56) 25 (14, 50) 0.11 37 (15, 61) 45 (26, 63) 34 (13, 57) 0.15 
mDF score≥32 (n, 
%) 
64 (49.2%) 25 (62.5%) 39 (43.3%) 0.044 89 (56.3%) 31 (64.6%) 58 (52.7%) 0.17 
ABIC score 
(mean±SD) 
7.4±1.5 7.6±1.4 7.3±1.6 0.39 7.8±1.3 7.7±1.3 7.8±1.3 0.82 
Outcomes 
   
 
    
Hospital stay, days 
(median, IQR) 
7 (4, 12) 7 (4, 12) 6 (4,12) 0.74 6 (3, 10) 6 (3, 10) 7 (3, 10) 0.75 
Attendance to 
alcohol 
rehabilitation within 
30 days after 
discharge  
(n, %) 
27 (20%) 3 (7.3%) 24 (25.5%) 0.02 19 (16.0%) 
(n=119) 
4 (8.2%) 
(n=49) 
15 (21.4%) 
(n=70) 
0.04 
Alcohol relapse 
within 30 days after 
discharge  
(n, %) 
50 (37%) 23 (56.1%) 27 (28.7%) 0.003 48 (34.0%) 
(n=141) 
27 (57.5%) 
(n=47) 
21 (22.3%) 
(n=94) 
<0.001 
*P-value comparing those who readmitted vs. who did not readmit in test cohort 1 
**P-value comparing those who readmitted vs. who did not readmit in validation cohort 2 
n/a = data not available in test cohort 3 
Abbreviations: ABIC = Age, serum Bilirubin, international normalized ratio, and serum Creatinine, 4 
BMI = body mass index, CTP= Child-Turcotte-Pugh Score, INR = international normalized ratio, 5 
mDF = Maddrey's Discriminant Function, MELD = Model for End-Stage Liver Disease, PT = 6 
prothrombin time 7 
 8 
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Table 2. Multivariable analyses of variables associated with 30-day readmission, 30-day alcohol 1 
relapse and mortality 2 
 3 
n/a = variables that were not statistically significant in univariate analysis 4 
 5 
 6 
 Test cohort Validation cohort 
 Multivariable logistic regression analysis 
30-day readmission Adjusted Odds Ratio P Adjusted Odds Ratio P 
Hepatic decompensation 2.14 (0.90-5.06) 0.08 1.95 (0.87-4.38) 0.10 
Total bilirubin 1.04 (1.01-1.09) 0.04 1.02 (0.99-1.06) 0.23 
Attendance to alcohol 
rehabilitation 
0.16 (0.04-0.65) 0.01 0.30 (0.09-0.98) 0.04 
 Multivariable logistic regression analysis 
30-day alcohol relapse Adjusted Odds Ratio P Adjusted Odds Ratio P 
College degree or above n/a  0.74 (0.31-1.77) 0.50 
MELD score  0.98 (0.89-1.07) 0.60 0.97 (0.90-1.04) 0.36 
Child-Turcotte-Pugh Score  0.79 (0.53-1.17) 0.23 0.82 (0.60-1.12) 0.20 
Attendance to alcohol 
rehabilitation 
0.11 (0.02-0.53) <0.001 0.09 (0.01-0.73) 0.02 
 Multivariable Cox regression analysis 
Mortality Adjusted Hazard Ratio P Adjusted Hazard Ratio P 
Age 1.01 (0.98-1.03) 0.79 1.04 (1.01-1.08) 0.04 
Male 0.74 (0.41-1.32) 0.30 0.79 (0.41-1.58) 0.49 
Hepatic decompensation n/a  2.11 (1.01-4.99) 0.04 
Variceal bleeding 11.1 (2.52-34.4) 0.004 n/a  
ABIC score n/a  1.12 (0.81-1.55) 0.49 
Attendance to alcohol 
rehabilitation 
0.20 (0.05-0.56) 0.001 0.20 (0.01-0.94) 0.04 
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What You Need to Know   
Background: Patients admitted to the hospital for alcoholic hepatitis (AH) are at increased risk of hospital 
readmission and death. 
Findings: In two cohort of patients admitted with AH, early alcohol rehabilitation reduced risk of hospital 
readmission, alcohol relapse, and death. 
Implications for patient care: All patients with AH should be formally evaluated by addiction specialists 
during hospital stay and referred for treatment within 30 days of hospital discharge. 
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Supplemental Table 1.  Patient characteristics of those who attended vs. not attended alcohol 
rehabilitation  
 Test cohort Validation cohort 
 All patients Attended 
alcohol 
rehabilitation 
Did not 
attend 
alcohol 
rehabilitation 
P* All patients** Attended 
alcohol 
rehabilitation 
Did not 
attend 
alcohol 
rehabilitation 
P*** 
 (n=135) (n=27) (n=108)  (n=119) (n=19) (n=100)  
Age, years 
(mean±SD) 
48.0±10.2 47.6±12.1 48.1±9.7 0.84 50.0±11.0 44.7±11.3 51.7±11.3 0.02 
Male (n, %) 90 (66.7%) 17 (63.0%) 73 (67.6%) 0.65 72 (60.5%) 10 (52.6%) 62 (62%) 0.44 
Married or living 
with significant other 
(n, %) 
42 (31.1%) 8 (29.6%) 19 (70.4%) 0.85 43 (39.5%) 9 (52.9%) 34 (37.0%) 0.22 
College degree or 
above (n, %) 
n/a n/a n/a  53 (48.6%) 14 (82.4%) 39 (42.4%) 0.003 
Average number of 
drinks/day 
(median, IQR) 
n/a n/a n/a  8 (5, 13) 8 (5, 20) 7 (5, 12) 0.46 
Hepatic 
decompensation (n, 
%) 
49 (36.3%) 39 (36.1%) 10 (37.0%) 0.93 76 (63.9%) 13 (68.4%) 63 (63.0%) 0.65 
- Hepatic 
encephalopathy (n, 
%) 
17 (12.6%) 3 (11.1%) 14 (13.6%) 1.00 25 (21.0%) 3 (15.8%) 22 (22.0%) 0.76 
- Variceal bleeding 
(n, %) 
3 (2.2%) 0 (0%) 3 (2.8%) 1.00 20 (16.8%) 4 (21.1%) 16 (16.0%) 0.52 
- Ascites (n, %) 53 (39.3%) 12 (44.4%) 41 (38.0%) 0.54 65 (54.6%) 13 (68.4%) 52 (52%) 0.19 
Severity scores 
        
MELD score 
(mean±SD) 
20.5±7.2 22.6±8.9 20.0±6.6 0.17 21.8±7.2 21.8±5.8 21.6±7.2 0.88 
CTP score 
(mean±SD) 
8.9±1.5 8.9±1.7 8.9±1.5 0.87 9.5±1.8 9.5±1.9 9.4±1.7 0.84 
mDF score (median, 
IQR) 
30 (16, 50) 28 (19, 65) 31 (16, 49) 0.40 37 (15, 61) 41 (15, 69) 34 (15, 59) 0.46 
mDF score≥32 (n, 
%) 
64 (49.2%) 12 (46.2%) 52 (50.0%) 0.73 64 (54.2%) 11 (57.9%) 53 (53.5%) 0.73 
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Outcomes 
   
 
    
Hospital stay, days 
(median, IQR) 
7 (4, 12) 7 (4, 14) 6 (4,10) 0.35 6 (3, 10) 6 (3, 13) 7 (3, 10) 0.56 
Addiction medicine 
consult attempt 
96 (71.1%) 22 (81.5%) 74 (68.5%) 0.18 n/a n/a n/a  
Addiction medicine  
consult completed 
87 (64.4%) 22 (81.5%) 65 (60.2%) 0.04 n/a n/a n/a  
 
*P-value comparing those who readmitted vs. who did not readmit in test cohort 
**Validation cohort in this table only include patients with available alcohol rehabilitation data 
***P-value comparing those who readmitted vs. who did not readmit in validation cohort 
n/a = data not available  
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Supplemental Table 2. Univariate logistic regression analysis for predictors of alcohol rehabilitation 
attendance 
n/a* = not enough data for analysis (only 5 patients who were non-white and only 3 patients with 
variceal bleeding in test cohort)  
n/a = data not available 
 Test cohort Validation cohort 
 
Variables Odds ratio P Odds ratio P 
Age (per 1 year) 0.99 (0.95-1.04) 0.81 0.95 (0.90-0.99) 0.01 
Male 0.82 (0.34-1.96) 0.65 0.68 (0.45-0.25) 0.45 
BMI 0.97 (0.91-1.03) 0.32 1.04 (0.97-1.12) 0.27 
White n/a*  0.80 (0.20-3.12) 0.75 
Married or living with significant other 0.92 (0.37-2.30) 0.85 1.92 (0.68-5.44) 0.22 
College degree or above n/a  6.34 (1.70-23.6) 0.002 
Average number of drinks/day n/a  1.02 (0.96-1.08) 0.57 
Hepatic decompensation 1.04 (0.43-2.95) 0.93 1.27 (0.45-3.63) 0.65 
Hepatic encephalopathy 0.84 (0.22-3.16) 0.79 0.66 (0.18-2.49) 0.53 
Variceal bleeding n/a*  1.40 (0.41-4.77) 0.59 
Ascites 1.31 (0.56-3.07) 0.54 2.0 (0.70-5.68) 0.18 
Platelet 1.00 (0.99-1.00) 0.77 1.00 (0.99-1.01) 0.90 
Albumin 1.41 (0.64-3.11) 0.39 1.86 (0.98-3.52) 0.05 
Creatinine 1.63 (1.05-2.51) 0.02 0.59 (0.19-1.82) 0.25 
Total bilirubin  1.11 (0.34-3.64) 0.86 1.01 (0.96-1.06) 0.68 
INR 1.40 (0.71-2.78) 0.34 1.27 (0.53-3.05) 0.59 
PT 1.01 (0.92-1.01) 0.86 1.03 (0.94-1.13) 0.52 
MELD score 1.05 (0.99-1.08) 0.10 1.00 (0.94-1.08) 0.89 
Child-Turcotte-Pugh Score 0.97 (0.73-1.30) 0.85 1.04 (0.77-1.39) 0.82 
mDF score 1.01 (0.99-1.02) 0.47 1.01 (0.99-1.02) 0.49 
mDF score ≥32 0.86 (0.36-2.03) 0.73 1.19 (0.44-3.22) 0.73 
ABIC score 1.17 (0.88-1.55) 0.29 0.66 (0.43-1.01) 0.05 
Addiction medicine consult completed 2.91 (1.02-8.27) 0.03 n/a  
Addiction medicine consult attempt 2.02 (0.71-5.79) 0.17 n/a  
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Supplemental Table 3. Multivariate logistic regression analysis for predictors of alcohol rehabilitation 
attendance  
 
  
 Test cohort Validation cohort 
 
Variables Odds ratio P Odds ratio P 
Age (per 1 year) n/a  0.95 (0.90-1.00) 0.05 
College degree or above n/a  4.62 (1.19-17.9) 0.03 
Creatinine 1.53 (0.99-2.37) 0.06 n/a  
Addiction medicine consult completed 2.55 (0.88-7.37) 0.08 n/a  
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Supplemental Table 4. Univariate logistic regression analysis for predictors of 30-day readmission 
 
n/a = data not available in test cohort 
 
 Test cohort Validation cohort 
 
Variables Odds ratio P Odds ratio P 
Age (per 1 year) 0.99 (0.95-1.03) 0.53 0.98 (0.95-1.01) 0.21 
Male 1.31 (0.59-2.90) 0.51 1.08 (0.55-2.14) 0.82 
BMI 1.00 (0.95-1.05) 0.85 0.98 (0.93-1.03) 0.36 
White 0.64 (0.10-4.00) 0.64 0.75 (0.29-1.92) 0.55 
Married or living with significant 
other 
1.22 (0.56-2.67) 0.62 1.32 (0.65-2.66) 0.44 
College degree or above n/a  1.23 (0.61-2.47) 0.56 
Average number of drinks/day n/a  0.95 (0.85-1.07) 0.41 
Hepatic decompensation 2.87 (1.34-6.14) 0.006 1.37 (0.66-2.86) 0.40 
Hepatic encephalopathy 1.73 (0.61-4.92) 0.30 0.68 (0.30-1.54) 0.36 
Variceal bleeding 4.77 (0.42-54.1) 0.21 1.15 (0.45-2.89) 0.77 
Ascites 1.76 (0.84-3.71) 0.14 1.16 (0.59-2.31) 0.66 
Platelet 1.01 (0.99-1.01) 0.08 1.00 (0.99-1.00) 0.73 
Albumin 0.60 (0.30-1.19) 0.14 0.73 (0.43-1.23) 0.22 
Creatinine 0.78 (0.47-1.30) 0.31 1.14 (0.79-1.64) 0.48 
Total bilirubin  1.04 (1.01-1.08) 0.009 1.01 (0.98-1.04) 0.51 
INR 1.52 (0.65-3.55) 0.34 1.27 (0.69-2.33) 0.45 
PT 1.02 (0.94-1.10) 0.64 1.04 (0.98-1.11) 0.20 
MELD score 1.03 (0.98-1.08) 0.23 1.04 (0.99-1.09) 0.09 
Child-Turcotte-Pugh score 1.26 (0.97-1.62) 0.08 1.18 (0.96-1.44) 0.10 
mDF score 1.01 (1.00-1.02) 0.14 1.01 (0.99-1.02) 0.29 
mDF score ≥32 2.18 (1.02-4.68) 0.04 1.63 (0.81-3.29) 0.17 
ABIC score 1.11 (0.86-1.43) 0.41 0.97 (0.75-1.26) 0.82 
Attendance to alcohol rehabilitation 0.23 (0.07-0.81) 0.02 0.33 (0.10-0.99) 0.04 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplemental Table 5. Univariate logistic regression analysis for predictors of 30-day alcohol relapses 
n/a* = not enough data for analysis (only 5 patients who were non-white and only 3 patients with 
variceal bleeding in test cohort)  
n/a** = data not available in test cohort 
 Test cohort Validation cohort 
 
Variables Odds ratio P Odds ratio P 
Age (per 1 year) 1.00 (0.97-1.04) 0.91 1.01 (0.98-1.04) 0.47 
Male 0.54 (0.26-1.13) 0.10 0.95 (0.89-0.47) 0.89 
BMI 0.99 (0.95-1.04) 0.82 0.99 (0.95-1.04) 0.82 
White n/a*  0.54 (0.19-1.49) 0.24 
Married or living with significant 
other 
1.07 (0.50-2.7) 0.86 0.62 (0.29-1.33) 0.22 
College degree or above n/a**  0.45 (0.21-0.95) 0.04 
Average number of drinks/day n/a**  0.99 (0.95-1.03) 0.54 
Hepatic decompensation 0.64 (0.31-1.35) 0.24 1.20 (0.64-0.56) 0.64 
Hepatic encephalopathy 0.48 (0.15-1.57) 0.20 0.48 (0.15-1.57) 0.20 
Variceal bleeding n/a*  1.78 (0.71-4.47) 0.22 
Ascites 0.61 (0.29-1.27) 0.18 0.75 (0.37-1.51) 0.42 
Platelet 1.00 (0.99-1.00) 0.83 0.99 (0.99-1.00) 0.41 
Albumin 2.51 (1.24-5.08) 0.01 1.20 (0.74-1.96) 0.46 
Creatinine 0.52 (0.27-0.98) 0.02 1.01 (0.66-1.53) 0.97 
Total bilirubin  0.97 (0.93-1.00) 0.05 0.95 (0.91-0.99) 0.004 
INR 0.33 (0.12-0.91) 0.02 0.43 (0.20-0.91) 0.02 
PT 0.89 (0.81-0.98) 0.01 0.91 (0.84-0.98) 0.007 
MELD score 0.93 (0.87-0.99) 0.01 0.92 (0.87-0.98) 0.005 
Child-Turcotte-Pugh Score 0.76 (0359-0.97) 0.03 0.78 (0.63-0.97) 0.02 
mDF score 0.98 (0.97-0.99) 0.02 0.98 (0.97-0.99) 0.003 
mDF score ≥32 0.80 (0.39-1.65) 0.55 0.36 (0.17-0.73) 0.005 
ABIC score 0.80 (0.62-1.02) 0.07 0.82 (0.62-1.09) 0.16 
Attendance to alcohol rehabilitation 0.10 (0.02-0.44) 0.002 0.07 (0.08-0.51) 0.009 
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Supplemental Table 6. Univariate Cox regression analysis for predictors of mortality 
 
n/a = data not available in test cohort 
 Test cohort Validation cohort 
 
Variables Hazard ratio P Hazard ratio P 
Age (per 1 year) 1.01 (0.98-1.04) 0.44 1.06 (1.03-1.09) <0.001 
Male 0.88 (0.51-1.55) 0.66 0.87 (0.45-1.75) 0.69 
BMI 1.00 (0.97-1.04) 0.80 0.98 (0.94-1.03) 0.46 
White 0.79 (0.24-4.84) 0.74 2.17 (0.79-8.97) 0.20 
Married or living with significant 
other 
0.60 (0.29-1.23) 0.13 1.37 (0.71-2.62) 0.34 
College degree or above n/a  0.81 (0.41-1.55) 0.52 
Average number of drinks/day n/a  0.99 (0.95-1.03) 0.60 
Hepatic decompensation 1.16 (0.66-2.00) 0.59 2.05 (1.02-4.56) 0.04 
Hepatic encephalopathy 0.87 (0.36-1.81) 0.72 1.39 (0.68-2.65) 0.35 
Variceal bleeding 12.32 (2.92-35.44) 0.002 1.25 (0.56-2.51) 0.56 
Ascites 0.90 (0.51-1.56) 0.72 1.51 (0.81-2.90) 0.20 
Platelet 0.99 (0.99-1.00) 0.25 0.99 (0.99-1.00) 0.37 
Albumin 0.82 (0.48-1.39) 0.47 0.88 (0.55-1.34) 0.57 
Creatinine 0.75 (0.45-1.12) 0.22 0.93 (0.56-1.25) 0.69 
Total bilirubin  1.00 (0.97-1.02) 0.99 0.98 (0.95-1.02) 0.36 
INR 1.59 (0.84-2.81) 0.13 1.41 (0.80-2.36) 0.21 
PT 1.05 (0.99-1.10) 0.05 1.02 (0.97-1.08) 0.40 
MELD score 1.00 (0.96-1.04) 0.93 1.00 (0.96-1.04) 0.93 
Child-Turcotte-Pugh Score 1.09 (0.91-1.32) 0.34 1.16 (0.96-1.40) 0.12 
mDF score 1.01 (1.00-1.01) 0.23 1.00 (0.99-1.01) 0.66 
mDF score ≥32 1.47 (0.85-2.57) 0.17 1.21 (0.66-2.26) 0.53 
ABIC score 1.02 (0.85-1.22) 0.82 1.42 (1.13-1.78) 0.002 
Attendance to alcohol rehabilitation 0.20 (0.05-0.55) 0.001 0.15 (0.01-0.68) 0.009 
